IDH2 mutations in acute myeloid leukemia

References

• Babakhanlou R, Ravandi-Kashani F. SOHO state of the art updates and next questions - The role of maintenance therapy in acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2023;23(1):1–7. doi:10.1016/j.clml.2022.11.003
   PubMed Web of Science ®Google Scholar
• Montalban-Bravo G, DiNardo C. The role of IDH mutations in acute myeloid leukemia. Future Oncol. 2018;14(10):979–993. doi:10.2217/fon-2017-0523
   PubMed Web of Science ®Google Scholar
• Pollyea DA, Kohrt HE, Medeiros BC. Acute myeloid leukaemia in the elderly: a review. Br J Haematol. 2011;152(5):524–542. doi:10.1111/j.1365-2141.2010.08470.x
   PubMed Web of Science ®Google Scholar
• Nassereddine S, Lap CJ, Haroun F, et al. The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia. Ann Hematol. 2017;96(12):1983–1991. doi:10.1007/s00277-017-3161-0
   PubMed Web of Science ®Google Scholar
• Knick Ragon B, DiNardo C. Targeting IDH1 and IDH2 mutations in acute myeloid leukemia. Curr Hematol Malig Rep. 2017;12(6):537–546. doi:10.1007/s11899-017-0418-6
   PubMed Web of Science ®Google Scholar
• Dang L, Yen K, Attar EC. IDH mutations in cancer and progress toward development of targeted therapeutics. Ann Oncol. 2016;27(4):599–608. doi:10.1093/annonc/mdw013
   PubMed Web of Science ®Google Scholar
• McMurry H, Fletcher L, Traer E. IDH inhibitors in AML – promise and pitfalls. Curr Hematol Malig Rep. 2021;16(2):207–217. doi:10.1007/s11899-021-00619-3
   PubMed Web of Science ®Google Scholar
• Reitman ZJ, Yan H. Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. J Natl Cancer Inst. 2010;102(13):932–941. doi:10.1093/jnci/djq187
   PubMedGoogle Scholar
• Fujii T, Khawaja MR, DiNardo CD, et al. Targeting isocitrate dehydrogenase (IDH) in cancer. Discovery Medicine. 2016;21(117):373–380.
   PubMed Web of Science ®Google Scholar
• Cerchione C, Romano A, Daver N, et al. IDH1/IDH2 inhibition in acute myeloid leukemia. Front Oncol. 2021;11:639387. doi:10.3389/fonc.2021.639387
   PubMedGoogle Scholar
• Marcucci G, Maharry K, Wu YZ, et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol. 2010;28(14):2348–2355. doi:10.1200/JCO.2009.27.3730
   PubMed Web of Science ®Google Scholar
• Paschka P, Schlenk RF, Gaidzik VI, et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol. 2010;28(22):3636–3643. doi:10.1200/JCO.2010.28.3762
   PubMed Web of Science ®Google Scholar
• Caramazza D, Lasho TL, Finke CM, et al. IDH mutations and trisomy 8 in myelodysplastic syndromes and acute myeloid leukemia. Leukemia. 2010;24(12):2120–2122. doi:10.1038/leu.2010.213
   PubMed Web of Science ®Google Scholar
• Pardanani A, Patnaik MM, Lasho TL, et al. Recurrent IDH mutations in high-risk myelodysplastic syndrome or acute myeloid leukemia with isolated del (5q). Leukemia. 2010;24(7):1370–1372. doi:10.1038/leu.2010.98
   PubMed Web of Science ®Google Scholar
• Stein E. IDH2 inhibition in AML: finally progress? Best Pract Res Clin Haematol. 2015;28(2–3):112–115. doi:10.1016/j.beha.2015.10.016
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Propert KJ, Loren AW, et al. Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. Blood. 2013;121(24):4917–4924. doi:10.1182/blood-2013-03-493197
   PubMed Web of Science ®Google Scholar
• Janin M, Mylonas E, Saada V, et al. Serum 2-hydroxyglutarate production in IDH1 and IDH2- mutated de novo acute myeloid leukemia: a study by the acute leukemia french association group. J Clin Oncol. 2014;32(4):297–305. doi:10.1200/JCO.2013.50.2047
   PubMed Web of Science ®Google Scholar
• Figueroa ME, Wahab OA, Lu C, et al. Leukemia IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010;18(6):553–567. doi:10.1016/j.ccr.2010.11.015
   PubMed Web of Science ®Google Scholar
• Ye D, Guan KL, Xiong Y. Metabolism, activity and targeting of D- and L-2- Hydroxyglutarates. Trends Cancer. 2018;4(2):151–165. doi:10.1016/j.trecan.2017.12.005
   PubMed Web of Science ®Google Scholar
• Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209–2221. doi:10.1056/NEJMoa1516192
   PubMed Web of Science ®Google Scholar
• Kernytsky A, Wang F, Hansen E, et al. IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition. Blood. 2015;125(2):296–303. doi:10.1182/blood-2013-10-533604
   PubMed Web of Science ®Google Scholar
• Guo JU, Su Y, Zhong C, et al. Emerging roles of TET proteins and 5-hydroxymethylcytosines in active DNA methylation and beyond. Cell Cycle. 2011;10(16):2662–2668. doi:10.4161/cc.10.16.17093
   PubMed Web of Science ®Google Scholar
• Mardis ER, Ding L, Dooling DJ, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med. 2009;361(11):1058–1066. doi:10.1056/NEJMoa0903840
   PubMed Web of Science ®Google Scholar
• Kosmider O, Gelsi-Boyer V, Slama L, et al. Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Leukemia. 2010;24(5):1094–1096. doi:10.1038/leu.2010.52
   PubMed Web of Science ®Google Scholar
• Heiblig M, Hachem-Khalife S, Willekens C, et al. Enasidenib for the treatment of relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase 2 mutation. Expert Rev Precis Med Drug Dev. 2020;5(6):421–428. doi:10.1080/23808993.2020.1831909
   Web of Science ®Google Scholar
• Patnaik MM, Hanson CA, Hodnefield JM, et al. Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo clinic study of 277 patients. Leukemia. 2012;26(1):101–105. doi:10.1038/leu.2011.298
   PubMed Web of Science ®Google Scholar
• Lasho TL, Jimma T, Finke CM, et al. SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival. Blood. 2012;120(20):4168–4171. doi:10.1182/blood-2012-05-429696
   PubMed Web of Science ®Google Scholar
• Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371(26):2488–2498. doi:10.1056/NEJMoa1408617
   PubMed Web of Science ®Google Scholar
• Zink F, Stacey SN, Norddahl GL, et al. Clonal hematopoiesis, with and without candidate driver mutations, is commonly in the elderly. Blood. 2017;130(6):742–752. doi:10.1182/blood-2017-02-769869
   PubMed Web of Science ®Google Scholar
• Welch JS, Ley TJ, Link DC, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell. 2012;150(2):264–278. doi:10.1016/j.cell.2012.06.023
   PubMed Web of Science ®Google Scholar
• Molenaar RJ, Thota S, Nagata Y, et al. Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms. Leukemia. 2015;29(11):2134–2142. doi:10.1038/leu.2015.91
   PubMed Web of Science ®Google Scholar
• Chou WC, Peng KY, Lei WC, et al. Persistence of mutant isocitrate dehydrogenase in patients with acute myeloid leukemia in remission. Leukemia. 2012;26(3):527–529. doi:10.1038/leu.2011.215
   PubMed Web of Science ®Google Scholar
• Debarri H, Lebon D, Roumier C, et al. IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the acute leukemia french association. Oncotarget. 2015;6(39):42345–42353. doi:10.18632/oncotarget.5645
   PubMedGoogle Scholar
• Malcovati L, Galli A, Travaglino E, et al. Clinical significance of somatic mutations in unexplained blood cytopenia. Blood. 2017;129(25):3371–3378. doi:10.1182/blood-2017-01-763425
   PubMed Web of Science ®Google Scholar
• Patel KP, Ravandi F, Ma D, et al. Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features. Leuk Lymphoma. 2023;135(1):1–11. doi:10.1309/AJCPD7NR2RMNQDVF
   Google Scholar
• DiNardo CD, Jabbour E, Ravandi F, et al. IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression. Leukemia. 2016;30(4):980–984. doi:10.1038/leu.2015.211
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Ravandi F, Agresta S et al.: Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML. Am J Hematol, 2015; 90(8): 732–736 doi:10.1002/ajh.24072
   PubMed Web of Science ®Google Scholar
• Boddu P, Takahashi K, Pemmaraju N, et al. Influence of IDH on FLT3-ITD status in newly diagnosed AML. Leukemia. 2017;31(11):2526–2529. doi:10.1038/leu.2017.244
   PubMed Web of Science ®Google Scholar
• Brunner AM, Neuberg DS, Wander SA, et al. Isocitrate dehydrogenase 1 and 2 mutations, 2-hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemia. Cancer. 2019;125(4):541–549. doi:10.1002/cncr.31729
   PubMed Web of Science ®Google Scholar
• Babakhanlou R, Ravandi-Kashani F. Non-intensive acute myeloid leukemia therapies for older patients. Expert Rev Hematol. 2023;16(3):171–180. doi:10.1080/17474086.2023.2184342
   PubMed Web of Science ®Google Scholar
• Xu Q, Li Y, Lv N, et al. Correlation between isocitrate dehydrogenase gene aberrations and prognosis of patients with acute myeloid leukemia: a systematic review and meta-analysis. Clin Cancer Res. 2017;23(15):4511–4522. doi:10.1158/1078-0432.CCR-16-2628
   PubMed Web of Science ®Google Scholar
• Patel JP, Gönen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366(12):1079–1089. doi:10.1056/NEJMoa1112304
   PubMed Web of Science ®Google Scholar
• Ravandi F, Patel K, Luthra R, et al. Prognostic significance of alterations in IDHEnzyme isoforms in patients with AMLTreated with High-Dose cytarabine andIdarubicin. Cancer. 2012;118(10):2665–2673. doi:10.1002/cncr.26580
   PubMed Web of Science ®Google Scholar
• Emadi A, Faramand R, Carter-Cooper B, et al. Presence of isocitrate dehydrogenase mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia. Am J Hematol. 2015;90(5):e77–e79. doi:10.1002/ajh.23965
   PubMed Web of Science ®Google Scholar
• Jin J, Hu C, Yu M, et al. Prognostic value of isocitrate dehydrogenase mutations in myelodysplastic syndromes: a retrospective cohort study and meta-analysis. PLOS One. 2014;9(6):e100206. doi:10.1371/journal.pone.0100206
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Patel KP, Garcia-Manero G, et al. Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents. Leuk Lymphoma. 2014;55(8):1925–1929. doi:10.3109/10428194.2013.855309
   PubMed Web of Science ®Google Scholar
• Mehta SV, Shukla SN, Vora HH. Overexpression of BCL-2 protein predicts chemoresistance in acute myeloid leukemia. Its correlation with FLT3. Neoplasma. 2013;60(6):666–675. doi:10.4149/neo_2013_085
   PubMed Web of Science ®Google Scholar
• Chan SM, Thomas D, Corces-Zimmerman MR, et al. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat Med. 2015;21(2):178–184. doi:10.1038/nm.3788
   PubMed Web of Science ®Google Scholar
• Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieved antitumor activity while sparing platelets. Nat Med. 2013;19(2):202–208. doi:10.1038/nm.3048
   PubMed Web of Science ®Google Scholar
• Jilg S, Reidel V, Müller-Thomas C, et al. Blockage of BCL-2 proteins efficiently induces apoptosis in progenitor cells of high-risk myelodysplastic syndromes patients. Leukemia. 2016;30(1):112–123. doi:10.1038/leu.2015.179
   PubMed Web of Science ®Google Scholar
• Konopleva M, Pollyea DA, Potluri J, et al. Efficacy and biological correlates of response in a phase 2 study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 2016;6(10):1106–1117. doi:10.1158/2159-8290.CD-16-0313
   PubMed Web of Science ®Google Scholar
• Cathelin S, Sharon D, Subedi A, et al. Combination of enasidenib and venetoclax shows superior anti-leukemic activity against IDH2 mutated AML in patient-derived xenograft models. Blood. 2018;132(Supplement 1):562–562. doi:10.1182/blood-2018-99-119688
   Google Scholar
• DiNArdo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617–629. doi:10.1056/NEJMoa2012971
   PubMed Web of Science ®Google Scholar
• Pollyea DA, DiNardo CD, Arellano ML, et al. Results of venetoclax and azacitidine combination in chemotherapy ineligible untreated patients with acute myeloid leukemia with IDH 1/2 mutations. Blood. 2020;136(Supplement 1):5–7. doi:10.1182/blood-2020-134736
   Google Scholar
• Lachowiez CA, Reville PK, Kantarjian H, et al. Contemporary outcomes in IDH-mutated acute myeloid leukemia: the impact of co-occurring NPM1 mutations and venetoclax-based treatment. Am J Hematol. 2022;97(11):1443–1452. doi:10.1002/ajh.26694
   PubMed Web of Science ®Google Scholar
• Pollyea DA, DiNardo CD, Arellano ML, et al. Impact of venetoclax and azacitidine in treatment-naïve patients with acute myeloid leukemia and IDH1/2 mutations. Clin Cancer Res. 2022;28(13):2753–2761. doi:10.1158/1078-0432.CCR-21-3467
   PubMed Web of Science ®Google Scholar
• Stein EM, DiNardo CD, Pollyea DA, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2021;137(13):1792–1803. doi:10.1182/blood-2017-04-779405
   PubMed Web of Science ®Google Scholar
• Montesinos P, Sanz MA. The differentiation syndrome in patients with acute promyelocytic leukemia: experience of the pethema group and review of the literature. Mediterr J Hematol Infect Dis. 2011;3(1):e2011059. doi:10.4084/MJHID.2011.059
   PubMedGoogle Scholar
• Fathi AT, DiNardo CD, Kline I, et al. Differentiation syndrome associated with enasidenib, a selective inhibitor of mutant isocitrate dehydrogenase 2: analysis of a phase ½ study. JAMA Oncol. 2018;4(8):1106–1110. doi:10.1001/jamaoncol.2017.4695
   PubMed Web of Science ®Google Scholar
• De Botton S, Montesinos P, Schuh AC, et al. Enasidenib vs. conventional care in older patients with late-stage mutant IDH2 relapsed/refractory AML: a randomized phase 3 trial. Blood. 2023;141(2):156–167. doi:10.1182/blood.2021014901
   PubMed Web of Science ®Google Scholar
• Pollyea DA, Tallman MS, de Botton S, et al. Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia. Leukemia. 2019;33(11):2575–2584. doi:10.1038/s41375-019-0472-2
   PubMed Web of Science ®Google Scholar
• DiNardo C, Schuh AC, Stein EM, et al. Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukemia (AG221-AML-005): a single-arm, phase 1b and randomized, phase 2 trial. Lancet Oncol. 2021;22(11):1597–1608. doi:10.1016/S1470-2045(21)00494-0
   PubMed Web of Science ®Google Scholar
• Venugopal S, Takahashi K, Daver N, et al. Efficacy and safety of enasidenib and azacytidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy. Blood Cancer J. 2022;12(1):10. doi:10.1038/s41408-021-00604-2
   PubMed Web of Science ®Google Scholar
• Atluri H, Maiti A, Sasaki K, et al. Phase Ib/2 study of oral decitabine/cedazuridine (ASTX727) and venetoclax in combination with the targeted mutant IDH1 inhibitor ivosidenib or the targeted mutant IDH2 inhibitor enasidenib in IDH mutated acute myeloid leukemia. Blood. 2022;140(Supplement 1):6170–6172. doi:10.1182/blood-2022-164986
   Google Scholar
• Quek L, David MD, Kennedy A, et al. Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib. Nat Med. 2018;24(8):1167–1177. doi:10.1038/s41591-018-0115-6
   PubMed Web of Science ®Google Scholar
• Stein EM, DiNardo CD, Fathi AT, et al. Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.  Blood. 2021;137(13):1792–1803. doi:10.1182/blood.2020007233
   PubMed Web of Science ®Google Scholar
• Bullinger L. IDH2 inhibition: another piece to the puzzle. Blood. 2019;133(7):625–626. doi:10.1182/blood-2018-12-891481
   PubMed Web of Science ®Google Scholar
• Chen EC, Li S, Eisfeld AK, et al. Outcomes for patients with IDH-mutated acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation. Transplant Cell Ther. 2021;27(6):479.e1 – 479–e7. doi:10.1016/j.jtct.2021.02.028
   Google Scholar
• Kunadt D, Stasik S, Metzeler KH, et al. Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation. J Hematol Oncol. 2022;15(1):126. doi:10.1186/s13045-022-01339-8
   PubMed Web of Science ®Google Scholar
• Fathi AT, Kim HT, Soiffer RJ, et al. Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies. Blood Adv. 2022;6(22):5857–5865. doi:10.1182/bloodadvances.2022008632
   PubMed Web of Science ®Google Scholar
• Zhuang X, Pei HZ, Li T, et al. The molecular mechanisms of resistance to IDH inhibitors in acute myeloid leukemia. Front Oncol. 2022;12:931462. doi:10.3389/fonc.2022.931462
   PubMedGoogle Scholar
• Wang F, Morita K, DiNardo CD, et al. Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia. Nat Commun. 2021;12(1):2607. doi:10.1038/s41467-021-22874-x
   PubMed Web of Science ®Google Scholar
• Amatangelo MD, Quek L, Shih A, et al. Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response. Blood. 2017;130(6):732–741. doi:10.1182/blood-2017-04-779447
   PubMed Web of Science ®Google Scholar
• Abelson S, Collord G, Ng SWK, et al. Prediction of acute myeloid leukemia risk in healthy individuals. Nature. 2018;559(7714):400–404. doi:10.1038/s41586-018-0317-6
   PubMed Web of Science ®Google Scholar